Dr. Michael Jung is a co-Founder and a member of the Scientific Advisory Board (SAB) of Athos Therapeutics Inc. He is a world-renowned medicinal chemist serving on the Scientific Advisory Boards of numerous biotech and pharmaceutical firms. He is an authority on synthetic organic and medicinal chemistry, holding more than 25 patents and being elected as a Fellow in the US National Academy of Inventors. He is on the Scientific Advisory Boards of several pharmaceutical firms and consults currently for more than 20 industrial laboratories in both the biotech and big pharma settings.
He received his Bachelor of Arts from Rice University and then his PhD in 1973 from Columbia, where he worked with Gilbert Stork. After a one-year NATO postdoctoral fellowship with Albert Eschenmoser at the ETH in Zurich, he joined the faculty at UCLA in 1974. He has risen through the ranks at UCLA and is now a Distinguished Professor of Chemistry & Biochemistry.
He has published more than 250 articles in refereed journals and has given over 470 lectures on his research. Importantly, he has designed 2 drugs (Enzalutamide, Erleada) that are currently FDA-approved for prostate cancer.